source
- FDA approves Bayer’s Sunharbo, first Factor XIa inhibitor to lower stroke recurrence riskThe Food and Drug Administration has approved Bayer's new medication intended to prevent another stroke in patients who have already experienced one. The drug, sold under the brand name Sunharbo,…
- Argenx to acquire peptide specialist Unnatural Products in deal worth up to $1.15 billionArgenx announced it will purchase Unnatural Products, a peptide discovery biotech, in a transaction that could total up to $1.15 billion. The deal provides $550 million upfront, with additional co…